Co-Tasmi Tablets 40/12.5Mg

Product Overview

Product Form: Tablet
Pack Size: 40 Tablets
Manufactured By: GETZ PHARMA PAKISTAN (PVT) LTD
Prescription Required: Yes

Product Details

Co-Tasmi Tablets 40/12.5mg are a combination medication containing two active ingredients, Telmisartan and Hydrochlorothiazide. Telmisartan is an angiotensin II receptor antagonist that helps relax blood vessels, improving blood flow and reducing blood pressure. Hydrochlorothiazide is a diuretic that helps reduce fluid retention by increasing urine output. Together, these ingredients are effective in managing hypertension (high blood pressure), especially in patients who may require a diuretic for additional blood pressure control.

Purposes

The primary purpose of Co-Tasmi Tablets 40/12.5mg is to treat hypertension (high blood pressure), helping to prevent complications such as stroke, heart attack, and kidney problems. This combination therapy is particularly useful for patients who have not responded adequately to monotherapy or need additional diuretic support to manage their blood pressure.

Warnings

• Kidney Impairment: Patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney should use 40/12.5mg with caution, as there is a risk of severe hypotension and renal impairment.
• Diabetes: Thiazide therapy can affect glucose tolerance, so diabetic patients may need adjustments to their insulin or oral hypoglycemic medications during use.
• Pregnancy: Avoid using this medication during the second and third trimesters of pregnancy, as it may cause harm to the fetus. Always consult your physician before use during pregnancy.

Adverse Effects

Common side effects of Co-Tasmi Tablets 40/12.5mg include dizziness, muscle cramps, dry mouth, and fatigue. Less common but more serious side effects can include hypokalemia (low potassium levels), hypotension, tachycardia, and liver dysfunction. In rare cases, patients may experience angioedema, allergic reactions, or increased uric acid levels.

Cautions

• Electrolyte Imbalance: 40/12.5mg should be used with caution in patients with hepatic impairment or electrolyte imbalances, as it can precipitate hepatic coma or worsen fluid and electrolyte disturbances.
• Monitor Renal Function: Regular monitoring of potassium, creatinine, and uric acid serum levels is advised, particularly for patients with mild to moderate renal impairment.
• Concomitant Medications: Avoid use with medications such as lithium, digoxin, and potassium-sparing diuretics, as they may interact with Co-Tasmi Tablets 40/12.5mg and increase the risk of adverse effects.

This alternative description ensures that Tablets 40/12.5mg are described in a clear, human-friendly manner, with all key information present.